

Brett Taylor Foxman, M.D., FASRS

Office Address :

1500 Tilton Road
Northfield, New Jersey 08225
Tel: (609) 646-5200

2466 E. Chestnut Ave.
Vineland, New Jersey 08361
Tel: (856) 507-0020

211 S. Main Street
Cape May Court House
New Jersey 08210
Tel: (609) 463-4610

Primary Activities:

Retina Specialist
Retinal and Ophthalmic Consultants, P.C.
Northfield, New Jersey
1992 – Present

Faculty and Staff Appointments:

1992 – Present	Attending Physician Shore Medical Center Somers Point, New Jersey
2021- Present 2008- 2021	Emeritus Chief, Division of Ophthalmology Chief, Division of Ophthalmology Shore Medical Center Somers Point, New Jersey
2014 – Present 1992 – 2014	Senior Medical Staff Attending Physician AtlantiCare Regional Medical Center Atlantic City, New Jersey
1992 - 2010	Consulting Physician Betty Bacharach Rehabilitation Hospital Pomona, New Jersey
1998 - 2008	Courtesy Staff Scheie Eye Institute University of Pennsylvania Health System Philadelphia, PA
1990 - 1992	Visiting Assistant Professor University of California, Los Angeles Jules Stein Eye Institute Department of Ophthalmology Los Angeles, California

1985 - 1987 Guest Investigator
The Rockefeller University
Laboratory of Biophysics
New York, New York

1984 - 1987 Assistant Attending Physician
The Burke Rehabilitation Center
White Plains, New York

Education and Postgraduate Training:

1990 - 1992 Retina Fellow
University of California, Los Angeles
Jules Stein Eye Institute
Dept. of Ophthalmology, Retina Division
Los Angeles, California

1987 - 1990 Ophthalmology Resident
University of California, Los Angeles
Jules Stein Eye Institute
Department of Ophthalmology
Los Angeles, California

1983 - 1987 Graduate Student and Postdoctoral Fellow
New York Hospital/
Cornell University Medical College
Department of Neurology
New York, New York

1982 - 1983 Intern
Framingham Union Hospital/
Boston University Affiliated Hospitals
Framingham, Massachusetts

1976 - 1982 Undergraduate and Medical Student
Boston University Medical Honors Program
Boston University School of Medicine
Boston, Massachusetts
Doctor of Medicine, 1982
Bachelor of Arts, 1982

Awards and Certifications:

Fellow of the American Society of Retina Specialists - 2021
United States Patent 10,251,634 Scleral Depressor - 2019
American Society of Retina Specialists Honor Award - March, 2005
Rhett Buckler Award, the Vitreous Society - November, 2001
The Vitreous Society Honor Award - November, 2001
Frances Howard Goldwyn Fellowship, Jules Stein Eye Institute/UCLA - July, 1991
Abe Meyer Fellowship, Jules Stein Eye Institute/UCLA - July, 1990
National Research Service Award, National Institutes of Health - January, 1986
Medical License, State of New Jersey
Medical License, State of New York (inactive)

Medical License, Commonwealth of Pennsylvania
Diplomat, American Board of Ophthalmology
Diplomat, National Board of Medical Examiners
Bachelor of Arts, cum laude, Boston University-May, 1982

Current Professional Societies:

American Society of Retina Specialists
American Academy of Ophthalmology
American Board of Ophthalmology
American Medical Association
Atlantic County Medical Society
Medical Society of New Jersey

Additional Prior Appointments:

Film Festival Chairperson, American Society of Retina Specialists 2007-2018
Board of Directors, American Society of Retina Specialists 2003-2008
Board of Directors, American Retina Foundation, Jacksonville, Florida 1997-2004
Editor in Chief, Retina Times (Formerly Vitreous Society Times) 2002-2004
Editor, Vitreous Society Online Journal 1998-2004
Webmaster, American Society of Retina Specialists (formerly the Vitreous Society) 1996-2005
Executive Board, Atlantic County Medical Society

Publications and National or International Lectures:

Foxman BT. A novel scleral depressor for use in vitrectomy surgery. Retina. 2018 Nov; 38(11):2275-2276.

Shields CL, Materin MA, Mehta S, Foxman BT, Shields JA. Regression of extrafoveal choroidal osteoma following photodynamic therapy. Arch Ophthalmol. 2008;126(1):135–137.

Shields JA, Perez N, Shields CL, Foxman S, Foxman B. Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surg Lasers 2002; 33:323-325.

Foxman, B Cosmetic Retina Surgery

Film presentation at the Vitreous Society 19th annual meeting
Puerto Rico, November, 2001

Winner of Rhett Buckler Award

Foxman BT, Foxman SG, Margolis, T FRS Radio Communications for the Office

E-Poster presentation at the Vitreous Society 19th annual meeting
Puerto Rico, November, 2001

Pavan PR, Foxman BT, et al. Internet Services of the Vitreous Society

Poster presentation at the Vitreous Society 18th annual meeting
Cancun, Mexico, January, 2001

Pavan PR, Foxman BT, Pinnolis M, Levitan M and Luloh P. Update of the Vitreous Society's Internet Services

Presented at the 1999 Vitreous Society annual meeting
Rome, Italy, September, 1999

Foxman BT and Pavan PR. Web Page Construction

Mini-course/discussion group

Presented at the 1999 Vitreous Society annual meeting
Rome, Italy, September 1999

Pavan PR and Foxman BT. Using the World Wide Web.

Course presented at the 1997 annual meeting of the American Academy of Ophthalmology, San Francisco, California, October 28, 1997, and to the 1997 Vitreous Society Annual Meeting, New Orleans, Louisiana, October, 1997.

Foxman BT and Pavan PR. Vitreous Society Online Update.

Presented to the 1997 Vitreous Society Annual Meeting, New Orleans, Louisiana, September, 1997.

Foxman BT, Pavan PR, Grizzard WS and Vitreous Society Communications Committee. Welcome to the Vitreous Society Online.

Presented to the 1996 Vitreous Society Annual Meeting,
Cancun, Mexico, December, 1996.

Pavan PR and Foxman BT. Surfing the Internet.

Course presented at the 1996 Vitreous Society Annual Meeting Cancun, Mexico, December, 1996.

Yoshizumi MO, Kreiger AE, Lewis H, Foxman B & Hakakha BA. Vitrectomy techniques in late-stage Coats'-like exudative retinal detachment. Documenta Ophthalmologica 90: 387-394, 1995

Yoshizumi MO, Kreiger AE, Lewis H, Foxman BT. Vitrectomy techniques in late stage Coats' Disease.

Presented to the Retina Society, New York, NY, September 26, 1992.

Foxman BT. A disposable double-lumen needle for gas-fluid exchange.

Presented at the Jules Stein Eye Institute Third Annual Research and Alumni Day,. Los Angeles, California, February 1, 1992.

Foxman BT, Rodriguez F, Lublin M, Lewis H. Results of photocoagulation for diabetic macular edema in patients with cystoid macular edema or ischemia.

Presented at the Jules Stein Eye Institute Second Annual Research and Alumni Day, Los Angeles California, February 2, 1991.

Foxman BT. Rationale for the development of an intraocular visual prosthesis. Proceedings of the 21st Annual Neural Prosthesis Workshop, 1990.

Presented at the 21st Annual Neural Prosthesis Workshop, National Institutes of Health, Bethesda, Maryland, October 17-19, 1990.

Foxman BT. Feasibility study and plans for the development of an intraocular neurosensory prosthesis.

Presented at the Jules Stein Eye Institute Research and Alumni Day, Los Angeles, California, March 10, 1990.

Foxman BT and Victor JD. A VEP Study of interactions due to flicker and drift. Proceedings of the Ninth Annual Conference of the IEEE Engineering in Medicine and Biology Society, Boston, Massachusetts, November 13-16, 1987. pp. 966-7.

Foxman BT and Victor JD. A VEP Study of flickering and moving gratings. Investigative Ophthalmology and Visual Science (Suppl.): 297, 1987.
Presented to the Association for Research in Vision and Ophthalmology, Sarasota, Florida, May 7, 1987.

Foxman BT, Oppenheim J, Petito CK, Gazzaniga Ms. Proportional anterior commissure area in humans and monkeys. Neurology 36: 1513-1517, 1986.

Foxman BT, Oppenheim J, Petito CK, Gazzaniga Ms. Proportional anterior commissure area in humans and monkeys. Neurology 35 (Suppl.1): 245, 1985.
Presented to the American Academy of Neurology May 2, 1985, and at the Vincent du Vineaud Research Symposium May 7, 1985.

Sinclair SH, Nesler C, Foxman BT, Nichols CW, Gabbe S. Macular edema and pregnancy in insulin-dependent diabetes. American Journal of Ophthalmology 97: 154-167, 1984.

Research

RHONE-X GR41987 -Principal Investigator

F. Hoffmann-La Roche Ltd
November 2021 – 2022

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab (RO6867461) in Patients with Diabetic Macular Edema.

ALK001-P3001 Sub-Investigator

Alkeus Pharmaceuticals
October 2019- 2022

A Phase 2/3 multicenter, Randomized, Double-masked, Parallel-group< placebo-controlled study to investigate the safety, Pharmacokinetics, tolerability, and efficacy of AKL-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration.

Yosemite GR40349 – Principal Investigator

F. Hoffmann-La Roche Ltd
July 2018 – April 2022

Phase III, Multicenter, Randomized, Double-Masked, Active Comparator–Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema.

Aerpio AKB-9778-CI-5001 – Principal Investigator

Aerpio Therapeutics LLC
August 2017 – May 2018

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15MG Once Daily or 15MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.

Omaspect Extension Study of Spectri GX30191 – Sub-Investigator

F. Hoffman-La Roche Ltd
March 2017 – April 2018

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study.

TOGA-01 Phase II/III – Sub-Investigator

University of Virginia Department of Ophthalmology
February 2017 – October 2021

A Randomized, Double Masked, Placebo-Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration.

MAKO-OHR-1601 / Chiltern Study Code No. 35544 – Principal Investigator

OHR Pharmaceutical, Inc.
June 2016 – July 2017

Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.

Protocol W – Principal Investigator

DRCR.net
May 2016 – July 2018

Intravitreal Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk

Capella R2176-3-AMD-1417 – Sub-Investigator

Regeneron
September 2015 – September 2016

A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration.

Spectri GX29185 – Sub-Investigator

F. Hoffman-La Roche Ltd
August 2014 – April 2018

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.

SCORE2 – Sub-Investigator

National Eye Institute, National Institutes of Health, Department of Health and Human Services
March 2014 - 2015

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2): A Multicenter, Prospective, Randomized, Phase III Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks Versus Intravitreal Aflibercept Every 4 Weeks.

ORBIT TG-MV-018 – Sub-Investigator

ThromboGenics, Inc.
February 2014 - 2015

A Multicenter, Prospective, Observational Phase 4 Study That Will Assess Clinical Outcomes and Safety of Jetrea Administered in a Real-World Setting for the Treatment of Symptomatic Vitreomacular Adhesion (VMA) by Assessing Anatomical and Functional Outcomes in 1500 Patients Recruited Across Approximately 120 USA Retina Sites.

Eclipse OPH1002A – Sub-Investigator

Ophthotech Corp
September 2013 – August 2016

A Phase III Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration.

BAM 114341 – Principal Investigator

Glaxo Smith Kline
March 2013 - 2015

A phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

VGFTe-AMD-1124 – Sub-Investigator

Regeneron
January 2013 - 2014

An Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration.

Protocol S – Principal Investigator

DRCR.net
July 2012 – April 2018

Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Protocol V – Principal Investigator

DRCR.net
July 2012 – July 2018

Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

Vibrant VGFT e-RVO-1027 – Sub-Investigator

Regeneron
June 2012 - 2013
Protocol: VGFT e-RVO-1027

A double-masked, randomized, active-controlled study of the efficacy, safety and tolerability of intravitreal administration of VEGF Trap-Eye (Intravitreal aflibercept injection(IAI) in patients with macular edema secondary to branch retinal vein occlusion.

Sakura – Principal Investigator

Santen Incorporated
2011 - 2013
Protocol No. 32-007

A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.

Vista – Sub-Investigator

Regeneron
2011 - 2013
VGFT-OD-1009

Shore – Sub-Investigator

Genentech
2011 - 2013
BB-IND 8633-Protocol FVF4967g:

A Multi-Center Randomized Study Evaluating Dosing Regimens For Treatment With Intravitreal Ranibizumab Injections In Subjects With Macular Edema Following Retinal Vein Occlusion

VIEW 1 Extension – Sub-Investigator

Regeneron
2010 - 2012
Protocol: VGFT-OD-0910

Open-label, long-term, safety and tolerability extension study of intravitreal VEGF Trap-Eye in neovascular age-related macular degeneration.

NAION

Covance
2009 – April 2018
Protocol: 12912

Prospective case crossover study to assess whether PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for the development of non-arteritic anterior ischemic optic neuropathy (NAION).

COPERNICUS – Sub-Investigator

Regeneron
2009 - April 2012
Protocol: VGFT-OD-0819

Randomized, Double-masked, controlled phase III study of the efficacy, safety and tolerability of repeated administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).

HARBOR – Sub-Investigator

Genentech
2009 - 2012
Protocol: FVF4579G

Phase III, double-masked, multi-center, randomized, active treatment, controlled study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly or on an as-needed-basis (PRN) in patients with subfoveal neovascular age-related macular degeneration.

RISE – Sub-Investigator

Genentech
2008 - 2012
Protocol: FVF4170G

Three year multi center study with monthly visits for patients with Diabetic Macular Edema comparing Lucentis with Standard of Care Laser treatments.

CRUISE – Sub-Investigator

Genentech
2008 - 2010
Protocol: FVF41669

One year multi center study with monthly visits comparing Lucentis to sham procedure for patients with central retinal vein occlusion.

DAVINCI – Sub-Investigator

Regeneron
2008 - 2012
Protocol: VGFT-OD-0706

A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME).

HORIZON – Sub-Investigator

Genentech
2008 - 2010
Protocol: FVF3426G

An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech sponsored ranizumab study.

VIEW1 – Sub-Investigator

Regeneron
2007 - 2010

Protocol: VGFT-OD-0605

Two year multi center study with monthly visits comparing VEGF-Trap against Lucentis for patients with newly diagnosed age-related macular degeneration.

SIRIUS – Sub-Investigator

Allergan

2006 - 2008

Protocol: 211745-001-01

2 year multi center study comparing Sirna against Lucentis for age-related macular degeneration

NOTAL VISION HMP-V4 – Sub-Investigator

Notal Vision

2006 - 2007

Protocol: 20071801

Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD)

SAILOR – Sub-Investigator

Genentech, Inc.

2003 - 2007

Protocol: FVF3689G

One year multi center study to evaluate the safety and tolerability of Lucentis in newly diagnosed and previously treated subjects with age-related macular degeneration.